Clinical trials: Smoldering Myeloma
Smoldering Multiple Myeloma
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
- Trial name
- NCT02916771
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Dana-Farber Cancer Institute
Smoldering Multiple Myeloma
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma.
- Trial name
- NCT01302886
- Testing
- BHQ880
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Advanced Prostate Cancer
Whole Body MRI in Oncology
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice.
- Conditions
- Lymphoma, Advanced Prostate Cancer, Advanced Breast Cancer, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ONCO-MRI (NCT06895291)
- Testing
- Whole Body-Magnetic Resonance Imaging (WB-MRI)
- Where
- 3 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
This prospective, multicenter, observational study aims to identify molecular and immunological markers associated with disease progression in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM)
- Trial name
- PNRR-2022-1237 (NCT07214324)
- Testing
- Collection of biological material
- Where
- 4 sites in Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Multiple Myeloma, Smoldering Multiple Myeloma
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk…
- Trial name
- iStopMM (NCT03815279)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- Iceland
- Volunteers
- 80 people
- Sponsor
- Landspitali University Hospital
Multiple Myeloma, Smoldering Multiple Myeloma
Imaging in MGUS, SMM and MM
Background: Recent studies have shown that the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) have a high risk of progressing to multiple myeloma (MM).
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT01237054
- Testing
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade
- Trial name
- NCT02269592
- Where
- 7 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Background: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Researchers want to see if a combination drug treatment can help.
- Trial name
- NCT04933539
- Testing
- Dexamethasone, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
High Risk Smoldering Multiple Myeloma
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.
- Trial name
- NCT06745687
- Testing
- CM336
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma.
- Trial name
- NCT05014646
- Testing
- Cholestyramine, Leflunomide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma, Smoldering Multiple Myeloma
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
The goal of this clinical trial is to test the safety, tolerability, and efficacy of TG01 vaccination in patients with KRAS or NRAS mutation on codon 12/13 mutation who has multiple myeloma or high-risk smoldering multiple…
- Trial name
- NCT05841550
- Testing
- TG01
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks.
- Trial name
- NCT05640843
- Testing
- Whole Foods Plant-based Diet, Algae Omega 3 + Curcumin
- Where
- 8 sites in United States
- Volunteers
- 180 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of…
- Trial name
- LINKER-SMM2 (NCT07393282)
- Testing
- Linvoseltamab, Daratumumab
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 270 people
- Sponsor
- Regeneron Pharmaceuticals
Smoldering Multiple Myeloma
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.
- Trial name
- NCT01718899
- Testing
- PVX-410
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- OncoPep, Inc.
Monoclonal Gammopathy, Smoldering Myeloma
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve…
- Conditions
- Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
- Trial name
- NCT03591614
- Testing
- DKK1
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center